View in EDS

Eligibility and subsequent burden of cardiovascular disease of four strategies for blood pressure-lowering treatment: a retrospective cohort study.

Saved in:
Bibliographic Details
Title: Eligibility and subsequent burden of cardiovascular disease of four strategies for blood pressure-lowering treatment: a retrospective cohort study.
Authors: Herrett, Emily (AUTHOR), Gadd, Sarah (AUTHOR), Jackson, Rod (AUTHOR), Bhaskaran, Krishnan (AUTHOR), Williamson, Elizabeth (AUTHOR), van Staa, Tjeerd (AUTHOR), Sofat, Reecha (AUTHOR), Timmis, Adam (AUTHOR), Smeeth, Liam (AUTHOR)
Source: Lancet. Aug2019, Vol. 394 Issue 10199, p663-671. 9p.
Subjects: Hypertension epidemiology, Cardiovascular disease prevention, Medical protocols, Risk assessment, Databases, Evaluation research, Cardiovascular diseases, Research funding, Hypertension, Antihypertensive agents, Retrospective studies, Longitudinal method, Research methodology, Research, Blood pressure, Comparative studies, Economic aspects of diseases, Blood pressure measurement
Abstract: Background: Worldwide treatment recommendations for lowering blood pressure continue to be guided predominantly by blood pressure thresholds, despite strong evidence that the benefits of blood pressure reduction are observed in patients across the blood pressure spectrum. In this study, we aimed to investigate the implications of alternative strategies for offering blood pressure treatment, using the UK as an illustrative example.Methods: We did a retrospective cohort study in primary care patients aged 30-79 years without cardiovascular disease, using data from the UK's Clinical Practice Research Datalink linked to Hospital Episode Statistics and Office for National Statistics mortality. We assessed and compared four different strategies to determine eligibility for treatment: using 2011 UK National Institute for Health and Care Excellence (NICE) guideline, or proposed 2019 NICE guideline, or blood pressure alone (threshold ≥140/90 mm Hg), or predicted 10-year cardiovascular risk alone (QRISK2 score ≥10%). Patients were followed up until the earliest occurrence of a cardiovascular disease diagnosis, death, or end of follow-up period (March 31, 2016). For each strategy, we estimated the proportion of patients eligible for treatment and number of cardiovascular events that could be prevented with treatment. We then estimated eligibility and number of events that would occur during 10 years in the UK general population.Findings: Between Jan 1, 2011, and March 31, 2016, 1 222 670 patients in the cohort were followed up for a median of 4·3 years (IQR 2·5-5·2). 271 963 (22·2%) patients were eligible for treatment under the 2011 NICE guideline, 327 429 (26·8%) under the proposed 2019 NICE guideline, 481 859 (39·4%) on the basis of a blood pressure threshold of 140/90 mm Hg or higher, and 357 840 (29·3%) on the basis of a QRISK2 threshold of 10% or higher. During follow-up, 32 183 patients were diagnosed with cardiovascular disease (overall rate 7·1 per 1000 person-years, 95% CI 7·0-7·2). Cardiovascular event rates in patients eligible for each strategy were 15·2 per 1000 person-years (95% CI 15·0-15·5) under the 2011 NICE guideline, 14·9 (14·7-15·1) under the proposed 2019 NICE guideline, 11·4 (11·3-11·6) with blood pressure threshold alone, and 16·9 (16·7-17·1) with QRISK2 threshold alone. Scaled to the UK population, we estimated that 233 152 events would be avoided under the 2011 NICE guideline (28 patients needed to treat for 10 years to avoid one event), 270 233 under the 2019 NICE guideline (29 patients), 301 523 using a blood pressure threshold (38 patients), and 322 921 using QRISK2 threshold (27 patients).Interpretation: A cardiovascular risk-based strategy (QRISK2 ≥10%) could prevent over a third more cardiovascular disease events than the 2011 NICE guideline and a fifth more than the 2019 NICE guideline, with similar efficiency regarding number treated per event avoided.Funding: National Institute for Health Research. [ABSTRACT FROM AUTHOR]
Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 138181445
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Eligibility and subsequent burden of cardiovascular disease of four strategies for blood pressure-lowering treatment: a retrospective cohort study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Herrett%2C+Emily%22">Herrett, Emily</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gadd%2C+Sarah%22">Gadd, Sarah</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Jackson%2C+Rod%22">Jackson, Rod</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bhaskaran%2C+Krishnan%22">Bhaskaran, Krishnan</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Williamson%2C+Elizabeth%22">Williamson, Elizabeth</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22van+Staa%2C+Tjeerd%22">van Staa, Tjeerd</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sofat%2C+Reecha%22">Sofat, Reecha</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Timmis%2C+Adam%22">Timmis, Adam</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Smeeth%2C+Liam%22">Smeeth, Liam</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Lancet%22">Lancet</searchLink>. Aug2019, Vol. 394 Issue 10199, p663-671. 9p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Hypertension+epidemiology%22">Hypertension epidemiology</searchLink><br /><searchLink fieldCode="DE" term="%22Cardiovascular+disease+prevention%22">Cardiovascular disease prevention</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+protocols%22">Medical protocols</searchLink><br /><searchLink fieldCode="DE" term="%22Risk+assessment%22">Risk assessment</searchLink><br /><searchLink fieldCode="DE" term="%22Databases%22">Databases</searchLink><br /><searchLink fieldCode="DE" term="%22Evaluation+research%22">Evaluation research</searchLink><br /><searchLink fieldCode="DE" term="%22Cardiovascular+diseases%22">Cardiovascular diseases</searchLink><br /><searchLink fieldCode="DE" term="%22Research+funding%22">Research funding</searchLink><br /><searchLink fieldCode="DE" term="%22Hypertension%22">Hypertension</searchLink><br /><searchLink fieldCode="DE" term="%22Antihypertensive+agents%22">Antihypertensive agents</searchLink><br /><searchLink fieldCode="DE" term="%22Retrospective+studies%22">Retrospective studies</searchLink><br /><searchLink fieldCode="DE" term="%22Longitudinal+method%22">Longitudinal method</searchLink><br /><searchLink fieldCode="DE" term="%22Research+methodology%22">Research methodology</searchLink><br /><searchLink fieldCode="DE" term="%22Research%22">Research</searchLink><br /><searchLink fieldCode="DE" term="%22Blood+pressure%22">Blood pressure</searchLink><br /><searchLink fieldCode="DE" term="%22Comparative+studies%22">Comparative studies</searchLink><br /><searchLink fieldCode="DE" term="%22Economic+aspects+of+diseases%22">Economic aspects of diseases</searchLink><br /><searchLink fieldCode="DE" term="%22Blood+pressure+measurement%22">Blood pressure measurement</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: <bold>Background: </bold>Worldwide treatment recommendations for lowering blood pressure continue to be guided predominantly by blood pressure thresholds, despite strong evidence that the benefits of blood pressure reduction are observed in patients across the blood pressure spectrum. In this study, we aimed to investigate the implications of alternative strategies for offering blood pressure treatment, using the UK as an illustrative example.<bold>Methods: </bold>We did a retrospective cohort study in primary care patients aged 30-79 years without cardiovascular disease, using data from the UK's Clinical Practice Research Datalink linked to Hospital Episode Statistics and Office for National Statistics mortality. We assessed and compared four different strategies to determine eligibility for treatment: using 2011 UK National Institute for Health and Care Excellence (NICE) guideline, or proposed 2019 NICE guideline, or blood pressure alone (threshold ≥140/90 mm Hg), or predicted 10-year cardiovascular risk alone (QRISK2 score ≥10%). Patients were followed up until the earliest occurrence of a cardiovascular disease diagnosis, death, or end of follow-up period (March 31, 2016). For each strategy, we estimated the proportion of patients eligible for treatment and number of cardiovascular events that could be prevented with treatment. We then estimated eligibility and number of events that would occur during 10 years in the UK general population.<bold>Findings: </bold>Between Jan 1, 2011, and March 31, 2016, 1 222 670 patients in the cohort were followed up for a median of 4·3 years (IQR 2·5-5·2). 271 963 (22·2%) patients were eligible for treatment under the 2011 NICE guideline, 327 429 (26·8%) under the proposed 2019 NICE guideline, 481 859 (39·4%) on the basis of a blood pressure threshold of 140/90 mm Hg or higher, and 357 840 (29·3%) on the basis of a QRISK2 threshold of 10% or higher. During follow-up, 32 183 patients were diagnosed with cardiovascular disease (overall rate 7·1 per 1000 person-years, 95% CI 7·0-7·2). Cardiovascular event rates in patients eligible for each strategy were 15·2 per 1000 person-years (95% CI 15·0-15·5) under the 2011 NICE guideline, 14·9 (14·7-15·1) under the proposed 2019 NICE guideline, 11·4 (11·3-11·6) with blood pressure threshold alone, and 16·9 (16·7-17·1) with QRISK2 threshold alone. Scaled to the UK population, we estimated that 233 152 events would be avoided under the 2011 NICE guideline (28 patients needed to treat for 10 years to avoid one event), 270 233 under the 2019 NICE guideline (29 patients), 301 523 using a blood pressure threshold (38 patients), and 322 921 using QRISK2 threshold (27 patients).<bold>Interpretation: </bold>A cardiovascular risk-based strategy (QRISK2 ≥10%) could prevent over a third more cardiovascular disease events than the 2011 NICE guideline and a fifth more than the 2019 NICE guideline, with similar efficiency regarding number treated per event avoided.<bold>Funding: </bold>National Institute for Health Research. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=138181445
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S0140-6736(19)31359-5
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 9
        StartPage: 663
    Subjects:
      – SubjectFull: Hypertension epidemiology
        Type: general
      – SubjectFull: Cardiovascular disease prevention
        Type: general
      – SubjectFull: Medical protocols
        Type: general
      – SubjectFull: Risk assessment
        Type: general
      – SubjectFull: Databases
        Type: general
      – SubjectFull: Evaluation research
        Type: general
      – SubjectFull: Cardiovascular diseases
        Type: general
      – SubjectFull: Research funding
        Type: general
      – SubjectFull: Hypertension
        Type: general
      – SubjectFull: Antihypertensive agents
        Type: general
      – SubjectFull: Retrospective studies
        Type: general
      – SubjectFull: Longitudinal method
        Type: general
      – SubjectFull: Research methodology
        Type: general
      – SubjectFull: Research
        Type: general
      – SubjectFull: Blood pressure
        Type: general
      – SubjectFull: Comparative studies
        Type: general
      – SubjectFull: Economic aspects of diseases
        Type: general
      – SubjectFull: Blood pressure measurement
        Type: general
    Titles:
      – TitleFull: Eligibility and subsequent burden of cardiovascular disease of four strategies for blood pressure-lowering treatment: a retrospective cohort study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Herrett, Emily
      – PersonEntity:
          Name:
            NameFull: Gadd, Sarah
      – PersonEntity:
          Name:
            NameFull: Jackson, Rod
      – PersonEntity:
          Name:
            NameFull: Bhaskaran, Krishnan
      – PersonEntity:
          Name:
            NameFull: Williamson, Elizabeth
      – PersonEntity:
          Name:
            NameFull: van Staa, Tjeerd
      – PersonEntity:
          Name:
            NameFull: Sofat, Reecha
      – PersonEntity:
          Name:
            NameFull: Timmis, Adam
      – PersonEntity:
          Name:
            NameFull: Smeeth, Liam
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 24
              M: 08
              Text: Aug2019
              Type: published
              Y: 2019
          Identifiers:
            – Type: issn-print
              Value: 01406736
          Numbering:
            – Type: volume
              Value: 394
            – Type: issue
              Value: 10199
          Titles:
            – TitleFull: Lancet
              Type: main
ResultId 1